EyeGate Pharmaceuticals (EYEG)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	5.64 mm	5.64 mm	5.64 mm	5.64 mm	5.64 mm	5.64 mm
Cash burn (monthly)	312.68 k	(no burn)	1.20 mm	(no burn)	(no burn)	(no burn)
Cash used (since last report)	1.34 mm	n/a	5.13 mm	n/a	n/a	n/a
Cash remaining	4.31 mm	n/a	513.84 k	n/a	n/a	n/a
Runway (months of cash)	13.8	n/a	0.4	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

EYEG institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	19	5	+280.0%
Opened positions	15	1	+1400.0%
Closed positions	1	0	NEW
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	4.06 bn	3.34 mm	+121429.2%
Total shares	8.35 mm	9.68 mm	-13.8%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Intracoastal Capital	3.47 mm	$519.00 k	0.0%
Lincoln Park Capital Fund	3.28 mm	$491.00 k	0.0%
Lind Global Fund II	345.51 k	$269.00 k	0.0%
Bigger Capital Fund L P	289.54 k	$437.00 k	0.0%
AIGH Capital Management	255.56 k	$1.07 bn	NEW
Nantahala Capital Management	211.11 k	$886.66 mm	NEW
Alyeska Investment	180.78 k	$759.28 mm	NEW
ADAR1 Capital Management	172.60 k	$724.90 mm	NEW
Velan Capital Investment Management	122.22 k	$513.34 mm	NEW
Geode Capital Management	13.77 k	$57.84 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Rosalind Advisors	0.00	-2.30 mm	EXIT
AIGH Capital Management	255.56 k	+255.56 k	NEW
Nantahala Capital Management	211.11 k	+211.11 k	NEW
Alyeska Investment	180.78 k	+180.78 k	NEW
ADAR1 Capital Management	172.60 k	+172.60 k	NEW
Velan Capital Investment Management	122.22 k	+122.22 k	NEW
Geode Capital Management	13.77 k	+13.77 k	NEW
UBS UBS	8.32 k	+8.32 k	NEW
BLK BlackRock	1.61 k	+1.61 k	NEW
GWM Advisors	22.00	+22.00	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

EYEG insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Sep 24	Carmine N. Stengone	Common Stock	Buy	Acquire P	No	No	3.68	1,250	4.60 k	1,250
10 Sep 24	Aron Shapiro	Common Stock	Buy	Acquire P	Yes	No	3.6	3,000	10.80 k	3,000
19 Aug 24	Praveen Tyle	Common Stock	Buy	Acquire P	No	No	3.96	5,000	19.80 k	5,014
19 Aug 24	Walters-Hoffert Lisa	Common Stock	Buy	Acquire P	No	No	3.86	1,250	4.83 k	1,250
14 Aug 24	Melissa Tosca	Common Stock	Buy	Acquire P	No	No	3.21	2,000	6.42 k	13,599

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target

12 Nov 24

HC Wainwright & Co. analyst Yi Chen reiterates Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy and maintains $10 price target.